SCHEMBL35210441

SCHEMBL35210441

C#CCCOc1ccc(-c2noc(-c3ccc(O)cc3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.53
S1PR3 Q99500 1/20 0.53
NPC1 O15118 7/20 0.46
RAB9A P51151 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
MAPT P10636 4/20 0.46
HTT P42858 1/20 0.46
CXCR1 P25024 2/20 0.45
AOC3 Q16853 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
TP53 P04637 2/20 0.43
HSD17B10 Q99714 2/20 0.42
PKM P14618 1/20 0.42
S1PR5 Q9H228 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL35210430 0.87 S1PR1 (0.49) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL35210439 0.83 S1PR1 (0.67) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL21153753 0.83 S1PR1 (0.76) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL21153222 0.82 S1PR1 (0.55) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL35210453 0.80 NPC1 (0.64) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL19968904 0.76 STAT3 (0.54) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL3057134 0.75 RAB9A (0.74) S1PR1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL9522122 0.74 AOC3 (0.50) S1PR1S1PR3NPC1RAB9ASMN1; SMN2
SCHEMBL5859124 0.73 LTA4H (0.49)
SCHEMBL20968212 0.72 NR1H4 (0.59) S1PR1S1PR3NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION UNIVERSITY OF NOTRE DAME DU LAC (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION CYP8B1, SPOUT1, O60361 S1PR1 3111/4885S1PR3 2606/4885NPC1 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.